SEK609.50
2.40% yesterday
Stockholm, Jun 13, 05:30 pm CET
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Camurus Stock price

SEK609.50
-16.00 2.56% 1M
+59.00 10.72% 6M
+44.00 7.78% YTD
+45.50 8.07% 1Y
+484.50 387.60% 5Y
+543.50 823.48% 10Y
+543.50 823.48% 20Y
Stockholm, Closing price Fri, Jun 13 2025
-15.00 2.40%
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Key metrics

Market capitalization SEK36.56b
Enterprise Value SEK33.79b
P/E (TTM) P/E ratio 68.18
EV/FCF (TTM) EV/FCF 91.77
EV/Sales (TTM) EV/Sales 16.60
P/S ratio (TTM) P/S ratio 17.96
P/B ratio (TTM) P/B ratio 10.54
Revenue growth (TTM) Revenue growth 11.69%
Revenue (TTM) Revenue SEK2.04b
EBIT (operating result TTM) EBIT SEK629.38m
Free Cash Flow (TTM) Free Cash Flow SEK368.24m
Cash position SEK2.88b
EPS (TTM) EPS SEK9.16
P/E forward 42.32
P/S forward 14.02
EV/Sales forward 12.95
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Camurus forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Camurus forecast:

Buy
75%
Hold
25%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,036 2,036
12% 12%
100%
- Direct Costs 138 138
11% 11%
7%
1,898 1,898
12% 12%
93%
- Selling and Administrative Expenses 632 632
41% 41%
31%
- Research and Development Expense 635 635
12% 12%
31%
646 646
19% 19%
32%
- Depreciation and Amortization 17 17
15% 15%
1%
EBIT (Operating Income) EBIT 629 629
19% 19%
31%
Net Profit 548 548
22% 22%
27%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 256
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today